V67A Stock Chart & Stats
€0.44
-€0.02(-2.27%)
At close: 4:00 PM EST
€0.44
-€0.02(-2.27%)
Day’s Range― - ―
52-Week Range€0.15 - €1.06
Previous CloseN/A
Volume0.00
Average Volume (3M)11.11K
Market Cap
€10.91M
Enterprise Value€31.22
Total Cash (Recent Filing)€548.93K
Total Debt (Recent Filing)€17.42M
Price to Earnings (P/E)―
Beta1.09
Next Earnings
Aug 24, 2026EPS Estimate
<0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.66
Shares Outstanding62,078,396
10 Day Avg. Volume0
30 Day Avg. Volume11,114
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.82
Price to Sales (P/S)0.23
P/FCF Ratio-1.77
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.07
Revenue Forecast (FY)€76.49M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained top-line expansion to ~$69.5M TTM and ~30% revenue growth indicates the company is scaling distribution and product adoption across its channels. Over a multi-month horizon this underpins potential unit economics improvement and creates optionality to invest in margin recovery or market share gains.
Improved LeverageMaterial reduction in leverage (debt/equity ~0.48) improves financial flexibility and lowers refinancing and liquidity risk. With positive equity, the balance sheet is better positioned to support operating needs or strategic investments over the coming months without excessive default or covenant pressure.
Expanded Capital & Incentive ToolsAuthorization of an omnibus equity plan and Series B preferred creates durable tools for retention and orderly capital raises. Structurally this enhances the company’s ability to fund growth or shore up liquidity and align management incentives over the medium term, improving strategic flexibility.
Bears Say
Persistent UnprofitabilityDeep negative operating and net margins reflect structural issues in cost structure or pricing. Continued losses will erode reserves and limit reinvestment capacity, making it harder to reach sustainable profitability without substantive operational improvements or higher-margin product mix shifts.
Negative Cash GenerationOngoing cash burn forces reliance on external financing or equity issuance to fund operations. Over several months this increases dilution risk and interest burden, constrains the ability to execute strategic initiatives, and heightens vulnerability if capital markets tighten or costs spike.
Thin Gross MarginsLow gross margins limit the company’s ability to absorb fixed SG&A and R&D costs, reducing operating leverage as scale grows. In a distribution-driven pharma/nutraceutical business this structural margin constraint makes durable profit recovery harder without product mix improvement or cost transformation.
Cosmos Holdings News
V67A FAQ
What was Cosmos Holdings’s price range in the past 12 months?
Cosmos Holdings lowest stock price was €0.15 and its highest was €1.06 in the past 12 months.
What is Cosmos Holdings’s market cap?
Cosmos Holdings’s market cap is €10.91M.
When is Cosmos Holdings’s upcoming earnings report date?
Cosmos Holdings’s upcoming earnings report date is Aug 24, 2026 which is in 26 days.
How were Cosmos Holdings’s earnings last quarter?
Currently, no data Available
Is Cosmos Holdings overvalued?
According to Wall Street analysts Cosmos Holdings’s price is currently Overvalued.
Does Cosmos Holdings pay dividends?
Cosmos Holdings does not currently pay dividends.
What is Cosmos Holdings’s EPS estimate?
Cosmos Holdings’s EPS estimate is <0.01.
How many shares outstanding does Cosmos Holdings have?
Cosmos Holdings has 62,078,396 shares outstanding.
What happened to Cosmos Holdings’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Cosmos Holdings?
Currently, no hedge funds are holding shares in DE:V67A
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cosmos Holdings
Cosmos Health Inc. functions as a vertically integrated pharmaceutical firm, providing its own line of branded and generic medicines, nutraceuticals, non-prescription drugs, healthcare and infant products, medical devices, and various other goods. These are distributed via its established channels and an e-commerce marketplace. The company actively seeks, obtains, develops, and commercializes solutions designed to improve patients' well-being and health outcomes. Supporting these operations, it maintains distribution centers in both Greece and the United Kingdom, alongside a dedicated warehousing facility. Its clientele includes wholesale pharmaceutical distributors and independent retail pharmacies. Cosmos Health Inc. was established in 2009 and has its headquarters in Chicago, Illinois.